Nowadays, new in vitro diagnostic (IVD) tests that could help to identify the presence of cancer are still required. As always focused on the field of IVD antibody development, Creative Biolabs now offers a full range of MMP-7 antibody development services for cholangiocarcinoma screening and treatment monitoring. Our technical experts and scientists specialized in antibody generation are pleased to help you develop novel IVD antibodies for MMP-7 marker.
Matrix metalloproteinase-7 (MMP-7), also known as matrilysin, pump-1 protease (PUMP-1), or uterine metalloproteinase, is a secreted protease that belongs to the peptidase M10 family of matrix metalloproteinases (MMPs). MMP-7 plays a role in the breakdown of extracellular matrix in normal physiological processes, including reproduction, embryonic development, and tissue remodeling. Besides, it is involved in the pathogenesis of diseases such as arthritis and cancer metastasis. MMP-7 can break down proteoglycans, elastin, fibronectin, and casein. It lacks a conserved C-terminal hemopexin domain, which is the difference between MMP-7 and most of the other MMP family members. Studies have shown that MMP-7 is involved in wound healing due to its role in regulating the activity of defensins in the intestinal mucosa. It shows high expression levels in various human cancers.
Fig.1 Role of MMPs in BCC (basal cell carcinoma) and tumor growth. (Pittayapruek, P., 2016)
Cholangiocarcinoma (CCA) is an aggressive and fatal cancer with a tendency for local invasion and distant metastases. However, the therapeutic methods for CCA have been limited since this type of cancer is poorly responsive to chemotherapy and radiation therapy. In order to improve the survival rate, patients suffered from CCA must be diagnosed and treated as early as possible. Previous studies have demonstrated that MMP-7 is found to be potentially involved in tumor metastasis and be frequently expressed in CCA specimens. High expression of MMP-7 facilitates cancer invasion and angiogenesis through degrading extracellular matrix macromolecules and connective tissues. The elevation of serum MMP-7 levels has already been proven as a useful marker for detecting cholangiocarcinoma, especially in those patients with obstructive jaundice.
Fig.2 Serum levels of CEA, CA19-9, MMP-7, and MMP-9 in cholangiocarcinoma and control (benign biliary tract disease) patients. (Leelawat, K., 2009)
Above all, novel markers should be investigated to better diagnose cholangiocarcinoma to improve the survival rate of CCA patients. MMP-7 has been regarded as a promising biomarker for the diagnosis of CCA. As always focused on the spotlight of IVD antibody development, Creative Biolabs offers the most comprehensive MMP-7 antibody development services for the diagnosis and prognosis of cholangiocarcinoma, with the ability to serve clients around the world. Our services are flexible and can be customized to meet the special requirements of our clients. Moreover, we help develop high-quality IVD immunoassays of different formats, giving expert support in feasibility analysis, protocol establishment, assay design, validation, and kit production.
In addition to MMP-7 marker, Creative Biolabs also offers IVD antibody development services targeting other potential biomarkers of cholangiocarcinoma. If you are interested in what we offer, please do not hesitate to contact us for more information.
References
For Research Use Only.
